Three Big Ideas in Aging Research That Could Shift the Therapeutic Landscape

Drawing on new discussions from ARDD2025 in Copenhagen, the focus turns to how GLP-1s, IPF, and the gut microbiome are steering aging drug development

Over the past decade, aging research has transitioned from a mostly fundamental science practice, including a landmark introduction of 9 hallmarks of aging back in 2013 and its expanded version of 12 hallmarks in 2023, to a highly technical, multidisciplinary field with increasingly tangible practical potential.

This transformation is happening thanks to numerous advances in the biology of aging, including the emergence of age-specific biomarkers or “aging clocks,” senolytics, cell reprogramming, and many other promising directions.

But it is also enabled by the rapid advent of foundational technologies, such as artificial intelligence (AI), which has opened doors for more sophisticated biology modeling, better understanding of aging processes, and potentially new creative ideas for addressing humanity’s biggest current limitation: the inevitable decline and end of life.

In this issue: Is the first anti-aging drug class on the horizon? — Finding the missing link between aging research and clinical development — Do bacteria in our gut hold the key to healthspan and longevity?

Below, I would like to highlight several recent advances in aging research that can redefine the landscape of therapeutics development in this area, both R&D and business-wise. This is based on learnings from this year’s 12th Aging Research and Drug Discovery Meeting (ARDD2025) in Copenhagen, and my coverage of last year’s ARDD2024 event.

Is the first anti-aging drug class on the horizon?

During this year’s Aging Research and Drug Discovery Meeting, Andrew Adams, Group Vice President of Molecule Discovery at Eli Lilly, presented a thought-provoking case for GLP-1 receptor agonists as potentially the first class of longevity therapeutics, with both mechanistic relevance and clinical scale to be able to impact human healthspan on a global population scale.

Traditionally indicated for type 2 diabetes and obesity, GLP-1s such as semaglutide and tirzepatide have shown robust, multi-system benefits: reducing the progression from prediabetes to diabetes by up to 94%, significantly lowering cardiovascular events (MACE), and producing weight loss with downstream metabolic and inflammatory effects.

Adams emphasized the relevance of these outcomes in delaying the onset of chronic, age-related diseases, thus compressing morbidity, a core objective in longevity medicine. He further highlighted early signals suggesting GLP-1s may exert positive effects on vascular function, cognitive decline, and even psychiatric and addiction-related conditions, though he acknowledged that more evidence is needed in these emerging indications.

Importantly, he framed these drugs within a broader shift from “sick care” to proactive, preventive healthcare, suggesting that long-acting delivery formats, such as RNA-based or gene-editing approaches, could further extend their reach and adherence in aging populations.

While he did not claim GLP-1s reverse aging or extend maximum lifespan, Adams posed a critical question: are GLP-1s the first true longevity drug class, considering their scalable, evidence-based impact across age-related disease trajectories?

A similar perspective was reinforced during the same conference by , Chief Scientific Advisor at Novo Nordisk and . She opened her presentation with a striking and unambiguous title slide: “Semaglutide as a Proven Longevity Medicine,” as , Co-founder and CEO of , writes in .

To read the rest of this article, upgrade to a BiopharmaTrend Pro subscription.

Gain full access to all of our deep dives and content archives.

Upgrade to Pro

Already a member? Sign in here.